Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
Xencor Inc (XNCR)
Sector: Healthcare; Industry: Biotechnology

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-03-03 Eckert Celia VP, GENERAL COUNSEL Sell 444 $44.94 $19,955 No
2021-03-03 Desjarlais John R SR. VICE PRESIDENT & CSO Sell 1,165 $45.03 $52,454 No
2021-03-03 Dahiyat Bassil I PRESIDENT & CEO Sell 2,850 $44.88 $127,909 No
2021-03-03 Kuch John J SR. VICE PRESIDENT & CFO Sell 15,870 $48.71 $772,966 Yes
2020-12-17 Yang Allen SR. VICE PRESIDENT & CMO Sell 3,777 $43.85 $165,621 No
2020-04-06 STAFFORD JOHN S III 10%-Owner Sell 644,771 $27.43 $17,685,509 No
2020-03-20 Ronin Capital, LLC 10%-Owner Sell 77,570 $29.32 $2,274,236 No
2020-01-08 STAFFORD JOHN S III 10%-Owner Sell 125,785 $36.24 $4,558,228 No
2019-12-26 STAFFORD JOHN S III 10%-Owner Sell 212,939 $39.52 $8,415,520 No
2019-12-11 STAFFORD JOHN S III 10%-Owner Sell 410,500 $40.44 $16,599,484 No
2019-08-21 Kuch John J Sr. Vice President & CFO Sell 40,000 $41.27 $1,650,724 Yes
2019-08-19 Desjarlais John R Sr. V.P., Research & CSO Sell 35,000 $40.69 $1,424,150 No
2019-06-06 STAFFORD JOHN S III 10%-Owner Buy 12,641 $29.87 $377,587 No
2019-05-02 STAFFORD JOHN S III 10%-Owner Buy 14,611 $29.87 $436,407 No
2019-03-25 STAFFORD JOHN S III 10%-Owner Buy 5,500 $29.84 $164,115 No
2019-03-18 STAFFORD JOHN S III 10%-Owner Buy 39,400 $29.04 $1,144,356 No
2018-09-17 Foster Paul A Chief Medical Officer Sell 40,000 $46.03 $1,841,208 Yes
2018-09-14 STAFFORD JOHN S III 10%-Owner Sell 1,000 $48.05 $48,054 No
2018-08-17 Foster Paul A Chief Medical Officer Sell 3,659 $40.10 $146,726 Yes
2018-08-16 Foster Paul A Chief Medical Officer Sell 36,341 $41.10 $1,493,710 Yes
2018-08-13 Baracchini Edgardo Jr Chief Business Officer Sell 50,000 $40.16 $2,008,117 Yes
2018-08-10 Desjarlais John R Sr. V.P., Research & CSO Sell 35,000 $40.36 $1,412,721 Yes
2018-07-17 STAFFORD JOHN S III 10%-Owner Sell 111,700 $41.42 $4,626,479 No
2018-07-12 STAFFORD JOHN S III 10%-Owner Sell 138,300 $39.69 $5,489,265 No
2018-06-20 STAFFORD JOHN S III 10%-Owner Sell 250,000 $39.90 $9,974,392 No
2018-06-15 Dahiyat Bassil I President and CEO Sell 50,000 $40.51 $2,025,690 Yes
2018-06-13 Kuch John J Sr. Vice President & CFO Sell 25,000 $41.64 $1,040,945 Yes
2018-03-15 Baracchini Edgardo Jr Chief Business Officer Sell 40,000 $30.89 $1,235,744 Yes
2018-03-05 Baracchini Edgardo Jr Chief Business Officer Sell 20,000 $29.59 $591,806 Yes
2018-02-27 Baracchini Edgardo Jr Chief Business Officer Sell 20,000 $29.64 $592,848 Yes

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.

Insider Smart

PROSPECT CAPITAL CORP (PSEC) - PSEC is the 2nd most bought stock of the past 90 days by insiders, CEO seems very confident about the company.